Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-α antagonist
Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-α antagonist
复制标题
DOI：
10.1210/jc.2003-031929
复制
发表时间：
2004-09-01
影响因子：
5.8
通讯作者：
Chrousos, GP
中科院分区：
文献类型：
--
作者：
Vgontzas, AN;Zoumakis, E;Chrousos, GP
促炎性细胞因子TNF α和IL-6在阻塞性睡眠呼吸暂停（OSA）中升高，并且已被提出作为人类过度日间嗜睡的介质。我们在8名肥胖男性呼吸暂停患者中测试了依那西普的作用，依那西普是一种中和TNF α的药物，被FDA批准用于治疗类风湿性关节炎。这些患者参加了一项先导性、安慰剂对照、双盲研究，在此期间获得了夜间多导睡眠图、多次睡眠潜伏期试验、空腹血糖和IL-6、C-反应蛋白、胰岛素和脂联素的血浆水平。依那西普可显著减少嗜睡，使多次睡眠潜伏期试验中的睡眠潜伏期延长3.1 ± 1.0 min（P
The proinflammatory cytokines, TNFalpha and IL-6, are elevated in obstructive sleep apnea (OSA) and have been proposed as mediators of excessive daytime sleepiness in humans. We tested the effects of etanercept, a medication that neutralizes TNFalpha and is approved by the FDA for the treatment of rheumatoid arthritis, in eight obese male apneics. These patients participated in a pilot, placebo-controlled, double-blind study during which nighttime polysomnography, multiple sleep latency test, and fasting blood glucose and plasma levels of IL-6, C-reactive protein, insulin, and adiponectin were obtained. There was a significant and marked decrease in sleepiness by etanercept, which increased sleep latency during the multiple sleep latency test by 3.1+/-1.0 min (P